| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-22 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y201-03003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2015-03-09^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-02-13^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f9c9255cc643bfd94e6f3b71661803f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09fc4ac0c4e08cf51f4d4e410ec498d2 |
| publicationDate |
2018-02-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9890365-B2 |
| titleOfInvention |
Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
| abstract |
Non-viral delivery systems comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626382-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10781430-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020377866-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11732246-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459558-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11104887-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11685906-B2 |
| priorityDate |
2014-03-09^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |